Erdafitinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Erdafitinib. Educational only — not medical advice.
Labeled uses
BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] .
Source: FDA labeling via NIH DailyMed (set 2a8aa5c0…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.